You are here

Pharmacokinetics Of CP-690,550 In Patients With Impaired Renal Function

Last updated on May 9, 2018

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Orlando, Florida, 32806 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Renal Impairment
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-65 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Subjects with normal renal function: Subjects must be healthy with estimated
creatinine clearance >80 mL/min

- Subjects with renal impairment: Subjects should be in good general health commensurate
with the population with chronic kidney disease

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Kidney transplant patients

- Subjects with any condition possibly affecting drug absorption

- Subjects with malignancies with the exception of adequately treated basal cell
carcinoma of the skin

NCT01740362
Pfizer
Completed
Pharmacokinetics Of CP-690,550 In Patients With Impaired Renal Function

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Renal Impairment
NCT03542305
All Genders
18+
Years
Multiple Sites
Renal Cell Carcinoma
NCT02776644
All Genders
Renal Impairment
NCT03596567
All Genders
18+
Years
Multiple Sites
Metastatic Renal Cell Carcinoma
NCT03140176
All Genders
18+
Years
Multiple Sites
Pharmacokinetics Of CP-690,550 In Patients With Impaired Renal Function
Phase 1, Open-Label Study To Evaluate Single Dose Pharmacokinetics, Safety And Tolerability Of CP-690,550 In Patients With Impaired Renal Function
A study to evaluate the pharmacokinetics of CP-690,550 in subjects with mild, moderate or severe renal impairment, who do not require hemodialysis, compared to healthy controls.
Not Provided
Interventional
Phase 1
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Renal Impairment
Drug: CP-690,550
10 mg (2 x 5 mg tablets), single dose
  • Healthy volunteers
    Healthy volunteers
    Intervention: Drug: CP-690,550
  • Experimental: Mild renal impairment
    patients with mild (>50 and ?80 mL/min) renal impairment
    Intervention: Drug: CP-690,550
  • Experimental: Moderate renal impairment
    patients with moderate (?30 and ?50 mL/min) renal impairment
    Intervention: Drug: CP-690,550
  • Experimental: severe renal impairment
    patients with severe (<30 mL/min) renal impairment
    Intervention: Drug: CP-690,550
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
24
March 2004
March 2004   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subjects with normal renal function: Subjects must be healthy with estimated creatinine clearance >80 mL/min
  • Subjects with renal impairment: Subjects should be in good general health commensurate with the population with chronic kidney disease

Exclusion Criteria:

  • Kidney transplant patients
  • Subjects with any condition possibly affecting drug absorption
  • Subjects with malignancies with the exception of adequately treated basal cell carcinoma of the skin
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01740362
A3921006
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
December 2012

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now